Company Resverlogix Corp.

Stocks

RVX

CA76128M1086

Biotechnology & Medical Research

Market Closed - Toronto S.E. 14:50:43 2026-10-21 EDT			5-day change	1st Jan Change
0.0800 ^CAD	0.00%		-5.88%	-20.00%

09-10	Resverlogix Announces Publication Of Scientific Journal Articles Relating To Apabetalone's Prevention Of Heart Failure	CI
08-14	Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Business description: Resverlogix Corp.

Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Sales by Activity: Resverlogix Corp.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all business segments

Geographical breakdown of sales: Resverlogix Corp.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: Resverlogix Corp.

Manager	Title	Age	Since
Donald McCaffrey CEO	Chief Executive Officer	-	2003-04-24
Anthony Cann DFI	Director of Finance/CFO	78	2009-10-28
Ewelina Kulikowski CTO	Chief Tech/Sci/R&D Officer	-	2022-08-14
Michael Sweeney CTO	Chief Tech/Sci/R&D Officer	65	2014-11-02

See RESVERLOGIX CORP. governance

Composition of the Board of Directors: Resverlogix Corp.

Director	Title	Age	Since
Donald McCaffrey CHM	Chairman	-	2016-04-03
Kelly McNeill BRD	Director/Board Member	56	2009-10-14
Kenneth Zuerblis BRD	Director/Board Member	66	2010-09-28
Siu Lun To BRD	Director/Board Member	57	2019-12-18
Bradley J Glass BRD	Director/Board Member	-	2025-11-17

Composition of the Board of Directors

Shareholders: Resverlogix Corp.

Name	Stocks	%	Valuation
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 24.77 %	85,286,524	24.77 %	6 M $
Donald McCaffrey 1.529 %	5,263,266	1.529 %	357 902 $
Anthony Cann 0.6048 %	2,082,255	0.6048 %	141 593 $
Michael Sweeney 0.0451 %	155,312	0.0451 %	10 561 $
Kenneth Zuerblis 0.0311 %	107,062	0.0311 %	7 280 $

List of RESVERLOGIX CORP. shareholders

Company details: Resverlogix Corp.

Resverlogix Corp.

4820 Richard Road SW

T3E 6L1, Calgary

+403 254 9252

http://www.resverlogix.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RESVERLOGIX CORP.	0.00%	-5.88%	-23.81%	+14.29%	19.58M
WUXI APPTEC CO., LTD.	-0.21%	-4.43%	+44.40%	+74.13%	66.22B
ARGENX SE	-3.64%	-0.08%	+6.88%	+68.11%	55.2B
LONZA GROUP AG	+0.13%	+3.15%	+11.21%	+90.11%	52.79B
IQVIA HOLDINGS INC.	+3.28%	+5.58%	+26.51%	+50.05%	45.53B
BEONE MEDICINES AG	+0.51%	+9.95%	+22.40%	+133.92%	43.94B
REVOLUTION MEDICINES, INC.	-1.15%	+0.39%	+263.21%	+594.60%	41.64B
CELLTRION, INC.	+0.10%	+9.90%	+16.11%	+59.33%	34B
WUXI BIOLOGICS (CAYMAN) INC.	-8.38%	-6.95%	+26.35%	-1.93%	25.84B
GENMAB A/S	-0.74%	+2.85%	+35.47%	+25.47%	23.51B
Average	-1.01%	+3.08%	+42.87%	+110.81%	38.87B
Weighted average by Cap.	-0.81%	+3.72%	+49.20%	+125.85%